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Abstract 
Novel cationic dimethylaminopyridine derivatives of pentacyclic triterpenes were previously described to promote 
mitochondrial depolarization and cell death in breast and melanoma cell lines. The objective of this work was to 
further investigate in detail the mechanism of mitochondrial perturbations, correlating those effects with breast 
cancer cell responses to those same agents. Initially, a panel of tumor and non-tumor cell lines was grown in high-
glucose or glucose-free glutamine-containing media, the later forcing cells to synthesize ATP by oxidative 
phosphorylation only. Cell proliferation, cell cycle, cell death and mitochondrial membrane polarization were 
evaluated. Inhibition of cell proliferation was observed, accompanied by an arrest in the G1- cell cycle phase, and 
importantly, by loss of mitochondrial membrane potential. On a later time-point, caspase-9 and 3 activation were 
observed, resulting in cell death. For the majority of test compounds, we determined that cell toxicity was 
augmented in the galactose media. To investigate direct evidences on mitochondria isolated rat liver mitochondria 
were used. The results showed that the compounds were strong inducers of the permeability transition pore. 
Confirming our previous results, this work shows that the novel DMAP derivatives strongly interact with 
mitochondria, resulting in pro-apoptotic signaling and cell death. 
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1. Introduction 
Plants produce natural products as a defense against flora pathogens, with some of those products having important 
applications for humans.  Triterpenoids are a diverse group of phytochemicals, some of which presenting low 
biological toxicity and currently used in drug, cosmetic, dietary supplement and biocide industries, among others 
[25]. Triterpene molecules also have other clinically relevant properties [27], with the triterpenes betulin and 
betulinic acid in particular having received significant attention in this regard.  These compounds are of interest 
because of the potential for industrial-level manufacturing capabilities; the bark of birch trees (Betula papyrifera), 
currently a waste product of paper-processing plants, can be used to make extracts containing 72.4% and 5.4% of 
these compounds, respectively [25].  
Betulin and betulinic acid have a wide variety of potentially useful medical applications, including anti-
inflammatory and anti-cancer [45], anti-bacterial [1] and anti-viral properties [22,36]. Regarding anti-cancer 
activity,  Galgon et al. [17] showed that betulinic acid caused apoptosis in melanoma cells, later showing this 
activity to be specific for tumors derived from neuroectoderm [30].  Betulinic acid exhibits anti-cancer activity in 
many other malignancies as well, including leukemia, prostate, ovarian, breast, lung, and colon cancer [14]. 
Importantly, betulinic acid appears to display some degree of selectivity towards tumor cells, minimally affecting 
normal cells [16].  
Betulinic acid triggers apoptosis in cancer cells by triggering mitochondrial outer membrane permeabilization [15], 
which is an effective approach since cancer cells frequently develop defective apoptotic signaling, thus becoming 
resistant to traditional therapies [3]. In spite of these properties, clinical trials of betulinic acid and related 
compounds have proven disappointing.  Therefore, it is important to further investigate the structure-activity of 
betulinic acid derivatives, aimed at increasing the solubility of these compounds in water, reducing possible harmful 
side effects, and increasing the inhibition of tumor growth [25]. Toward this purpose, we have synthesized a number 
of semi-synthetic derivatives of lupane triterpenoids based on betulin and betulinic acid, and found that they display 
the ability to disrupt the mitochondrial membrane potential, resulting in the killing of melanoma and breast cancer 
cells [21] [7]. The present work investigates in detail the mechanism of action of some of these novel 
dimethylaminopyridine (DMAP) derivatives in breast cancer cells, when compared to normal mammary epithelial 
and stromal cells. Among the tested compounds, we have used those already evaluated in Holy et al. [21] in 
melanoma cells that showed to have some anti-tumoral activity, as well as a new group of compounds with slight 
modifications with the expectation of increasing their activity. Furthermore, we investigated the mechanism of 
action of these DMAP derivatives on isolated liver mitochondrial fractions in order to determine how they directly 
disrupt mitochondrial function.  The results of this study indicate that in general the DMAP compounds tested were 
more toxic to mammary tumor cells than non-transformed lines, and that they were able to induce the mitochondrial 
permeability pore transition, resulting in pro-apoptotic effects, G1 arrest, and cell death. 
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2. Material and Methods 
2.1. Reagents   
A full list of reagents is described in the Online Supplementary Material (OSM). 
2.2. Compounds 
The DMAP compounds used were synthesized using betulin and betulinic acid as basic natural precursors at the 
National Resources Research Institute at University of Minnesota, Duluth, USA (Fig.1). Betulin, isolated from the 
extract of outer birch bark of Betula papyifera and Betulinic acid, were used as backbone for the DMAP derivatives. 
Protocols for isolation and synthesis were as described in Holy et al. [21]. Briefly, through intermediate acylation of 
corresponding hydroxy groups with bromoacids and chloroacids, the reaction mixtures were heated up to 65°C 
overnight and poured into ethyl ether dropwise under stirring. The precipitatewas then filtered and washed twice 
with ethyl ether. All the compounds prepared were characterized by melting point, infrared (IV), nuclear magnetic 
resonance (1H NMR and 13C NMR) and mass spectrometry (MS), as described in Holy et al. [21]. The compounds 
4, 5 and 6 correspond to compounds 4, 11 and 12 respectively in the previous work by Holy et al. [21]. The 
remaining compounds, 1, 2, 3 and 7 are here tested for the first time.  
2.3. Cell Culture 
Human breast cancer cell lines MDA-MB-231 (92020424, ECACC, United Kingdom), MCF-7 (86012803, ECACC, 
United Kingdom) and HS578T (HTB-126, ATCC, Manassas, VA, USA) were used in this study. The normal human 
breast cell lines HS578Bst (HTB- 125, ATCC, Manassas, VA, USA), MCF-12A (CRL-10782, ATCC, VA, USA) 
and the normal human fibroblast BJ cell line (CRL- 2522, ATCC, Manassas, VA, USA) were used as non-tumor 
controls. Cells were cultured in high-glucose medium composed by Dulbecco’s modified Eagle’s medium (DMEM; 
D5648) supplemented with sodium pyruvate (0.11g/L), sodium bicarbonate (1.8g/L) and 10% Fetal bovine serum 
(FBS) and 1% of antibiotic penicillin-streptomycin 100x solution in 5% CO2 atmosphere at 37°C. Cells were also 
cultured in galactose/glutamine medium, prepared from glucose-free DMEM (D5030) supplemented with galactose 
(1.8g/L), L-glutamine (0.584g/L), sodium pyruvate(0.11g/L), sodium bicarbonate (1.8g/L), 10% FBS and 1% of 
antibiotic penicillin-streptomycin 100x solution in 5% CO2 atmosphere at 37°C. 
2.4. Cell Proliferation Measurement by the Sulforhodamine B method 
Cell proliferation measurements by using the sulforhodamine B assay were performed to evaluate the effect of all 
DMAP derivatives on the different cell lines, as previously described [38]. Compounds were added to cells in a 48-
well plate 24 hours after cell seeding (20,000 cells/ml). Vehicle controls were also performed. Cells were fixed and 
total cell mass was determined as previously described [43] 
2.5. Cell Cycle Analysis by flow cytometry 
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Cell cycle progression was analyzed by using flow cytometry [42]. Cells in log-phase growth were treated with 
different concentrations of the tested compounds for various lengths of time. Adherent and floating cells were then 
collected and fixed with cold 70% ethanol and stored overnight at -20°C. After washed and resuspended in PBS-T 
(132 mM NaCl, 4mM KCl; 1.2mM NaH2PO4, plus 0.1% Tween) samples were incubated at 37°C in 0.5 ml PBS-T 
with 20µg/ml RNase for 45 min, and with Propidium Iodide at 37°C, for further 30 min. The percentage of cells in 
the different cell cycle phases was quantified using a flow cytometer (Becton-Dickenson FACScalibur), with Modfit 
LT software (Verity Software House, Topsham, ME, USA). 
2.6. Live/Dead Assay by flow cytometry 
After treatment with DMSO or selected triterpenoids (compounds 2, 3, 5 and 7) at 1µg/ml for 24 and 48 hours, 
HS578T cells (initially seeded at 2.5x104 cells/ml in 6well-plates), were collected by trypsinization, centrifuged and 
resuspended in buffer solution (NaCl 120 mM, KCl 3.5 mM, KH2PO4 0.4 mM, HEPES 20 mM, NaHCO3 5 mM, 
NaSO4 1.2 mM and Glucose 15 mM). Cells were incubated for 15 min at 37°C with the Live–Dead kit (1 µM 
ethidium homodimer and 0.1 µM calcein-AM; Invitrogen, Eugene, OR). A Becton-Dickenson FACSalibur flow 
cytometer was used to measure FL1 (calcein, green) and FL3 (ethidium homodimer, red) signals. To quantify red 
and green fluorescence, CellQuest software verion 5.1 package was used. 
2.7. Caspases-like Activity Assay 
Attached and floating cells were collected by trypsinization and pellets were saved after centrifugation, in 
lysis/assay buffer (50 mM HEPES pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10% Glycerol and 10mM DTT) and 
frozen at -20ºC overnight. Protein quantification was determined by the Bradford method [26] using bovine serum 
albumin (BSA) as standard. To measure caspase 3 and 9-like activity, aliquots of cell extracts in ambar eppendorfs 
containing 25 mg (for caspase 3) or 50 mg (for caspase 9) were incubated in a reaction buffer containing 25 mM 
HEPES (pH 7.4), 10% sucrose; 10 mM DTT, 0.1% CHAPS and 100 mM caspase substrate (Ac-DEVD-pNA for 
caspase 3 or Ac-LEHD-pNA for caspase 9, purchased from Calbiochem, NJ, USA) for 2 h at 37°C. Caspase-like 
activities were determined by following the detection of the chromophore p-nitroanilide after cleavage of the labeled 
substrate Ac-DEVD-p-nitroanilide or AcLEHD-p-nitroanilide. The method was calibrated with known 
concentrations of p-nitroanilide, two hour later, at endpoint. 
2.8. Mitochondrial Proteins Semi-quantification by Western blotting  
For Western blot analyses, approximately 1.0x106 attached and floating cells were collected, including floating cells, 
resuspended and added to lysis buffer (20 mM HEPES/NaOH, pH 7.5, 250 mM sucrose, 10 mM KCl, 2 mM MgCl2, 
1 mM EDTA) supplemented with 2 mM dithiothreitol (DTT), 100 mM phenylmethylsulfonyl fluoride (PMSF) and a 
protease inhibitor cocktail. Afterwards, extracts were stored at -80°C and later analyzed by Western blotting, as 
described in the OSM.  
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2.9. Vital Epifluorescence Microscopy 
Images were obtained using a Nikon Eclipse TE2000U epifluorescence microscope. Cell lines were seeded in 6-well 
plates with a glass coverslip per well, at a density of 5-10x104 and allowed to attach for 24 hours. Cells were then 
treated with either the test compound solutions or the vehicle for the desired time. Thirty minutes prior the end of the 
treatment time, cells were incubated with TMRM (100 nM) in a buffer solution (NaCl 120mM, KCl 3.5mM, 
KH2PO4 0.4mM, HEPES 20mM, NaHCO3 5mM, NaSO4 1.2mM and glucose 15mM). The probe was maintained 
with cells during the imaging procedure in order to avoid extensive loss from mitochondria. 
2.10. Animals 
Male Wistar-Han rats (Charles River, Barcelona, Spain), 10 weeks old, were housed in our accredited animal colony 
(Laboratory Research Center, Faculty of Medicine of University of Coimbra). Animals were group-housed in type 
III-H cages (Tecniplast, Italy) and maintained in specific environmental requirements (22 °C, 45-65 % humidity, 15-
20 changes/hour ventilation, 12 h artificial light/dark cycle, noise level < 55 dB) and with free access to standard 
rodent food (4RF21 GLP certificate, Mucedola, Italy) and acidified water (at pH 2.6 with HCl to avoid bacterial 
contamination). This research procedure was carried out in accordance with European Requirements for Vertebrate 
Animal Research and according to the ethical standards for animal manipulation at the Center for Neuroscience and 
Cell Biology, University of Coimbra, Portugal. 
2.11. Isolation of Rat Liver Mitochondria   
Mitochondria were isolated from the livers of male Wistar rats by conventional differential centrifugation [29]. 
Livers were harvested and homogenized with buffer medium containing 250 mM sucrose, 10 mM HEPES (pH 7.4), 
1 mM EGTA and 0.1% BSA lipid-free. After obtaining a crude mitochondrial preparation, pellets were washed 
twice with 250mM sucrose and 10mM HEPES (pH 7.2). The protein content was determined by the biuret method, 
using BSA as a standard [20] .   
2.12. Measurement of Mitochondrial Oxygen Consumption 
A Clark-type oxygen electrode connected to a suitable recorder in a 1 mL thermo-stated, water-jacketed and closed 
chamber was used to measure the oxygen consumption of isolated liver mitochondria as previously described [41]. 
Further experimental details can be found in the OSM. 
2.13. Measurement of Mitochondrial Transmembrane Electric Potential  
The mitochondrial transmembrane electropotential (∆Ψ) was monitored indirectly, through the activity of the 
lipophilic cation tetraphenylphosphonium (TPP+), using a TPP+ selective electrode also connected to a suitable 
recorder in a 1 mL thermo-stated, water-jacketed and open chamber as previously described [34]. Mitochondrial 
protein (1.5 mg) was suspended in reaction medium composed of 125 mM sucrose, 65 mM KCl, 5 mM KH2PO4, 2.5 
mM MgCl2 and 5 mM HEPES (pH 7.4, 30°C), and supplemented with 3 µM TPP+. The compounds were added to 
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mitochondria for 1 min, followed by 10 mM succinate (plus 3µM rotenone). In order to initiate state 3 respiration, 
ADP (83.3 nmol/mg protein) was added. Assuming a Nernst distribution of the ion across the membrane electrode, 
the equation proposed by Kamo et al [23] without correction for passive membrane binding, was used to calculate 
the values for ∆Ψ.  
2.14. Induction of the Mitochondrial Permeability Transition Pore  
The turbidity of the mitochondrial suspension was measured at 540nm in a JASCO V-560 spectrophotometer after a 
single pulse of calcium (40mM) as described in the OSM.  
2.15. Statistics 
Data was analyzed in GraphPad Prism 5.0 software (GraphPad Software, Inc.), all results being expressed as means 
±SEM, and analyzed by the student’s T-test for comparison of two means, one-way ANOVA with Bonferroni or 
Dunnet multiple comparison post-test to compare groups with one independent variable; and two-way ANOVA for 
comparisons involving two independent variables. Values with p<0.05 were considered statistically significant. 
3. Results 
3.1. Breast cancer cell proliferation is inhibited by lupane triterpenoids 
The compounds used in this study are shown in Fig. 1.  To evaluate their effects on cell proliferation, a dose-
response assay using the SRB assay was performed (Fig.2). Monolayer cultures of human breast cancer cell lines 
MDA-MB-231, HS578T and MCF-7, and the non-tumorigenic cell lines MCF-12A (human breast epithelial cells) 
and BJ (human foreskin fibroblasts) were incubated in high-glucose medium with different concentrations of the 
compounds (0.125 - 2µg/ml) for 1, 3 and 5 days. 
Compounds 1 and 4 exhibited more toxicity toward normal cell lines than cancer cells, whereas compounds 5 and 6 
had similar effects on the proliferation of all cells lines tested. Compound 5 was the most toxic against cancer cells, 
having a more powerful effect against MDA-MB-231 cells (Fig.2C). 
Moreover, compound 2 was the less toxic molecule against the BJ cell line, not significantly affecting cell 
proliferation, and showing toxicity at the third day of treatment in all breast cancer cell lines. However, that same 
compound presented some toxicity on MCF-12A cells, already present in the first day of treatment. Compound 3 
reduced preferentially the cell numbers of the HS578T cell line for lower concentrations, with little effect on the 
normal cell lines. Structurally, compounds 5, 6 and 7 are very similar but compound 7 showed stronger effects in all 
cell lines tested, inhibiting cell proliferation on the first day of treatment for all cell lines except HS578T cells. 
When comparing cancer cell lines, the SRB data showed that both HS578T and MCF-7 cells were the most 
susceptible to the test compounds. Since HS578T cells are more aggressive due to their invasive capacity [32], this 
cell line was chosen for the following studies. To test the ability of this cell line to recover from DMAP treatment, 
HS578T cells were pulse-treated with compounds for 6 hours, followed by drug wash out and culture in fresh 
medium. In general, the 6-hour pulse of drug treatment at the higher concentrations still resulted in an inhibition of 
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proliferation 5 days after wash out, with the exception of compound 7, which showed stronger toxicity at the third 
day of treatment (Fig.2F). 
Typically, cancer patients receive a combination of chemotherapeutic drugs in attempts to reduce tumor cell growth, 
which allows for lower doses of each drug to be used, thereby reducing side-effects on non-tumor cells [13]. Thus, 
we next tested whether a combination of DMAP compounds and a number of commonly or historically used 
chemotherapeutics, including Paclitaxel (Taxol), Doxorubicin and Cisplatin were effective in suppressing HS578T 
cell growth over 3 days of treatment (Fig.A1). The objective was to combine compound concentrations that 
individually would inhibit cell proliferation by about 25%, in order to facilitate the detection of additive or 
synergistic effects. No additive or synergistic effects were observed with doxorubicin or cisplatin; however, 
combinations with Taxol showed a significant reduction of cell proliferation, especially when compound 2, 3 and 4 
were used, suggesting an additive effect of the combination. 
3.2. Lupane triterpenoids induce cell cycle arrest and cell death 
To distinguish between the contributions of cell cycle arrest vs. cell death in the proliferation experiments, the 
effects of the test compounds on the HS578T cell cycle was analyzed by flow cytometry. For this assay, a single 
compound concentration (0.5µg/ml) was used, corresponding approximately to 50% growth inhibition for the 
HS578T cell line verified for 24 and 48 hours. All the triterpenoids showed a similar pattern of cell cycle arrest, with 
an increase in the percentage of cells in G0/G1 phase and a decrease in the percentage of cells in S phase. For 
compound 4, a decrease in the percentage of cells in G2/M phase was also observed (Fig.3). 
Since compounds 2, 3, 5 and 7 inhibited cell proliferation, in part due to cell cycle arrest, the next question was 
whether the same compounds could cause cell death. Several experimental endpoints were measured to assess the 
induction of HS578T cell death (Fig.4). The assays included caspase-3 and 9-like activity, semi-quantification by 
Western blotting of proteins involved in cell death and mitochondrial integrity, as well as the Live/Dead assay to 
quantitatively measure cell viability. Live/Dead assays demonstrate that all compounds at a concentration of 1µg/ml 
modestly increased cell death at the two time points studied, 24h and 48h (Fig.4A). All compounds decreased the 
percentage of live HS578T cells by 10-20%, with the exception of compound 5, which had a milder effect. Caspase-
like assay activity assays demonstrate that a significant increase in caspase-9-like activity occurs after 24 hours of 
treatment with 1µg/ml of compounds 3, 5 and 7 (Fig. 4B). Compound 2 caused a small, non-statistically significant 
increase in caspase-9-like activity. Caspase-3-like activity was also increased in the presence of all tested 
compounds (Fig.4B). 
To complement the present results, proteins associated with cell death, such as Bcl-2 family proteins [10], p53 [39] 
and Cyclophilin D [4] were quantified by western blotting. An increase of total p53 protein was detected by western 
blot after treatment of HS578T cells with compounds 2, 3, 5 and 7 (Fig.4D). Similarily, cyclophilin D protein was 
found largely increased after treatment with all compounds, while no significant increase was observed for the pro-
apoptotic Bax protein, at least for the time point measured. Similarily, no differences were also obtained for the anti-
apoptotic Bcl-2 protein after treatment with compounds 2, 3, 5 and 7 (Fig.A2). 
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3.3. Mitochondrial structure and function are altered by lupane triterpenoids 
The previous results demonstrated that the new DMAP derivatives not only promoted cell cycle arrest, but also 
induced cell death. Since mitochondria are intrinsically involved in cell death, and following previous results from 
our group [21] [7], we next evaluated in situ mitochondrial effects of some of the selected compounds. To detect 
alterations in ∆Ψ, tetramethylrhodamine methylester (TMRM) a mitochondrial membrane potential-dependent 
fluorescent probe was used. Mitochondrial membrane potential (∆Ψ) alterations were studied in HS578T breast 
cancer cells, and compared with the non-transformed cell lines MCF12A and BJ cells. In addition, the HS578Bst 
cell line was also included, which is a normal mammary myoepithelial cell line genetically matched to the HS578T 
cells [46]. Cells were labeled with TMRM and its mitochondrial accumulation was observed by epifluorescence 
microscopy. Non-tumor cells appeared to have a more elongated and diffuse polarized mitochondrial network, while 
the 578T cancer cells showed a more polarized mitochondrial network located in the perinuclear region (Fig.5A). 
Moreover, fluorescent microscopy images also suggested that the baseline intensity of TMRM mitochondrial 
fluorescence was higher for the 578T cells than for the normal cell lines (Fig.5B).  
To test the effects of the DMAP compounds on mitochondrial polarization, compounds 2, 3, 5 and 7 were used and 
cells incubated with different concentrations (0.125µg/ml to 2µg/ml) for 6 hours. In general, the concentration of 
triterpenoids used appeared to preferentially affect the mitochondrial network in tumor breast cells (Fig.5A and B), 
leading to a thread-to-grain transition and loss of mitochondrial TMRM fluorescence intensity. The most toxic 
compound in terms of inducing mitochondrial depolarization appears to be 3, affecting transversely all cell lines. 
Compounds 2 and 7 affected preferentially the mitochondrial network of HS578Bst and HS578T cell lines, but in a 
milder manner when compared with compound 3. Compound 5 did not affect BJ or MCF-12A cells, a reduced effect 
on the HS578Bst cells, although promoting a decrease in TMRM fluorescence for the HS578T cell line. 
3.4. Effects of lupane triterpenoids under forced mitochondrial oxidative phosphorylation conditions   
To identify mitochondria as a direct target for DMAP derivatives, MDA-MB-231, MCF-7 and HS578T breast 
cancer cells were grown in a cell culture media which forces cells to rely solely on oxidative phosphorylation for 
ATP production. This glucose-free media contains galactose as carbon source and glutamine/pyruvate as 
mitochondrial substrates [28]. A dose-response SRB assay was used to evaluate compound toxicity. The test 
compounds significantly decreased MDA-MB-231 and MCF-7 cell number for all concentrations tested at the third 
and fifth days of treatment (Fig.6A and 6B, respectively, versus Fig.2), when comparing with results obtained with 
the high-glucose media. Surprisingly, the HS578T cell line, which was susceptible to the compounds under normal 
high-glucose media conditions, was now less affected than the other cell lines under these new conditions (Fig.6C). 
Still, compound 7 appeared to be the most toxic for that cell lines in all time points and concentrations tested. 
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3.5. Direct effects of lupane triterpenoids on mitochondrial oxidative phosphorylation – isolated mitochondrial 
fractions experiments 
Our results show that some of the DMAP compounds tested act directly on mitochondria in MCF-7 and MDA-MB-
231 cancer cells. To further understand how the different compounds interfere with mitochondrial function, isolated 
rat liver mitochondria were used to test their direct toxicity. By using isolated mitochondrial fractions, effects on 
other cellular structures can be excluded. Several parameters for mitochondrial function were evaluated including 
respiration, generation of ∆Ψ and induction of the MPT pore. Assays were performed by energizing mitochondria 
via complex II with succinate in the presence of rotenone (Table A1 in supplementary material). No effects on 
succinate-sustained respiration, regardless of the respiration state investigated were found after incubation with the 
compounds. The RCR and the ADP/O ratio of untreated fractions were indicative of well-coupled mitochondrial 
preparations and presented no alterations comparative to controls.    
Regarding the effects of DMAP derivatives on mitochondrial ∆Ψ, no effects were also observed for succinate-
energized preparations when compounds 5 and 7 were analyzed (Table A2 in supplementary data). However, 
compounds 2 and 3 decreased the depolarization caused by ADP for concentrations above 1.3 µg/mg and 0.7µg/mg 
of protein, respectively. Also, compound 3 decreased the ∆Ψmax for concentrations higher than 0.3 µg/mg of protein.  
Although no significant alterations were observed when respiration and mitochondrial ∆Ψ were measured, assays on 
intact cells showed that mitochondrial function was disturbed and cell death was promoted. A mitochondrial process 
associated with cell death is the MPT, which is related with an increase of mitochondrial inner membrane 
permeability to ion and solutes [6]. We have measured this event by following variations in pseudo-absorbance of 
the mitochondrial suspension in the presence of calcium. The results showed that compounds 2, 3 and 7 acted as 
MPT pore inducers in vitro. When compounds were pre-incubated with mitochondria and the MPT pore was 
induced with calcium, the amplitude of mitochondrial swelling increased in a dose-dependent manner (Fig. 7 A and 
B). For the highest concentration tested (1.33µg/mg), swelling amplitude was five times higher than in the control 
groups (calcium-only). Surprisingly, compound 5 did not have any effect on MPT induction. The MPT pore-
inducing effect of some of the compounds, occurring for concentrations where no respiration or ∆Ψ alterations were 
observed, was inhibited by cyclosporin A, a MPT pore desensitizer [8]. 
4. Discussion 
An important strategy in cancer cell chemotherapy is the re-activation of apoptotic pathways that may have been 
silenced or modified in tumor cells. In this context, mitochondria are a promising target to increase tumor 
susceptibility to chemotherapy-mediated death [19]. One characteristic of some cancer cells is increased 
mitochondrial ∆Ψ when compared with normal cells [44], which can drive the accumulation of positively charged 
molecules [5]. New cationic derivatives of lupane triterpenoids were already described as potential mitocans against 
human cancers [7,21].  The present work extends previous observations by investigating whether DMAP derivatives 
from the same family of compounds promote mitochondrial dysfunction and lead to selective killing of breast cancer 
cells, represented in this work by the MCF-7, HS578T and MDA-MB-231 human cell lines. Normal breast epithelial 
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MCF-12A and myoepithelial HS578Bst cells, as well as normal foreskin (BJ) fibroblasts, were used as non-tumor 
controls. The data shows that MCF-7 (Fig.2D) and HS578T (Fig.2E) cells are the cell lines most susceptible to 
inhibition of proliferation by the DMAP derivatives. Compounds 4, 5 and 6 were already tested in melanoma cells 
lines, in which compound 4 showed a weak effect, while compounds 5 and 6 were very active mitochondrial 
disturbers in melanoma cell models. In the present work, the target for anti-tumor activity was shifted to breast 
cancer. Together with previously analyzed compounds, we have tested four new derivatives. Interestingly, 
compound 5 did affect the usually resistant MDA-MB-231 cell line, which is a ‘triple-negative’ line (lacking 
overexpression of Her2/Neu, epidermal growth factor receptor, and estrogen receptor; [33]) as well as HS578T cells.  
Triple negative breast cancers are normally associated with a poor prognosis, and are therefore particularly 
important targets for more effective therapeutic strategies  [33](Fig.2C). Compounds 5 and 6 had similar effect on 
all cells tested, which is not surprising since their chemical structure is identical, differing only by the presence of a 
different counterion (Cl- or Br-, respectively), suggesting that this alteration does not interfere with cell proliferation, 
as previously described [21]. Moreover, both compounds 1 and 2 had similar effects, although compound 2 had a 
stronger effect overall. This small difference may result from a higher accumulation in cells since compound 2 
contains an extra nitrogen in the chemical structure, which may undergo protonation/deprotonation cycles and 
change the overall molecule charge. Furthermore, we investigated whether the toxicity of the DMAP molecules was 
persistent through pulse-exposure experiments (Fig.2F). The results show that the anti-proliferative effects of a short 
(6 hour) DMAP treatment are persistent over the time frame studied. Compound 7 showed the highest potency in 
this regard, with a strong persistent toxic effect for cell the concentrations tested. From these results we can roughly 
order the compounds based on strength of cell proliferation effects (1 < 6 < 4 < 5 < 2 < 3 < 7). 
Of the well-known previously established chemotherapeutics tested in this study, only Taxol showed additive effects 
with the DMAP compounds. Taxol is a clinically important anti-tumor agent, which functions by suppressing 
microtubule dynamics [18].  Interestingly, the acquisition of Taxol resistance in some types of tumors is associated 
with mitochondrial biogenesis [35]. Since our results demonstrate that the DMAP derivatives so far tested 
characteristically profound effects on mitochondrial function, it is possible that they could be used to augment Taxol 
toxicity, or delay the onset of resistance to Taxol.   
Overall, the data on this paper suggest that DMAP derivatives can induce cell cycle arrest and cell death. All the 
compounds tested demonstrated a similar cell cycle arrest pattern, with an increase of cells in G0/G1 phase, 
accompanied by a reduction in S-phase cells, being observed (Fig.3). This type of cell cycle block is normally 
associated with DNA damage, although other mechanisms can also cause such type of arrest. For instance, a down-
regulation of cyclin A, cyclin D3 and CDK4, can contribute to G0/G1 phase block, resulting from ROS production 
[2]. It is also clear that in addition to cell cycle arrest, DMAP triterpenoids are also potent inducers of cell death.  
Notably, compounds 2, 3, 5 and 7 appeared to be more effectively trigger cell death in cancer cells than normal 
cells. The results confirm the ability of the triterpenoids to induce breast cancer cell death (Fig. 4), possibly by 
inducing mitochondrial perturbations. The marked increase in cyclophilin-D expression (Fig.4D) suggests that 
triterpenoids may sensitize the MPT pore for opening in situ through increasing intra-mitochondrial stress [4]. 
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High accumulation of cations in mitochondria can lead to mitochondrial depolarization (Fig.5A) through several 
mechanisms, including induction of the MPT, charge-driven matrix depolarization or inhibition of the respiratory 
chain, disrupting mitochondrial function and structure, and promoting cell death [31]. Smaller molecules 
(compounds 7 and 3) promoted a larger mitochondrial membrane depolarization in all cells when compared with 
longer ones (compounds 2 and 5), preferentially depolarizing mitochondria in the breast cancer HS578T cell line. 
The different activity can be explained by the fact that longer side chain compounds maybe present an increased 
difficulty in permeating membranes or to be more susceptible to breakage.  
To further investigate the possible primary role of mitochondria in the mechanism of toxicity of the novel 
triterpenoid compounds, the cancer cell lines MCF-7, MDA-MB-231 and HS578T were cultured in 
galactose/glutamine media in order to force cells to exclusively use oxidative phosphorylation (OXPHOS) for ATP 
production [28]. With this strategy, direct toxicity of the DMAP derivatives on mitochondria was determined. Under 
these conditions, cancer cells up-regulate glutaminolysis and Krebs cycle activity to supply reducing equivalents for 
the respiratory chain [11]. Our results showed that the DMAP compounds dramatically inhibited the proliferation of 
MCF-7 and MDA-MB-231 cancer cells for all concentrations tested under these conditions. However, HS578T cells 
were less affected under galactose/glutamine growth conditions, despite the fact that this cell line was strongly 
affected by the test compounds when growing in normal high-glucose media. One possible explanation is that the 
compounds may also present an inhibitory effect on glycolysis, although we cannot exclude other targets. Direct 
evidences of mitochondrial effects of the compounds 2, 3, 5 and 7 were obtained by using isolated rat liver 
mitochondria. Isolated mitochondrial fractions are considered a prime biosensor to test compound toxicity [37] and 
to predict drug safety in the pharmaceutical industry [12]. Strikingly, compounds 2, 3 and 7 caused a dose-
dependent cyclosporin-A-sensitive induction of the MPT pore (Fig. 7). This may imply that these compounds have a 
direct effect on a pore component, or act through the induction of oxidative stress, since no effects on ∆Ψ or 
respiration (Tables A1 and A2) were noticed for the same range of concentrations in the absence of calcium. 
Contrarily, compound 5 had no effect on MPT pore opening, which is interesting since this compound has a similar 
structure to compound 2, differing by only two carbons. The difference may rely on the fact that compound 5 is a 
longer molecule, which may interfere with its ability to bind to its targets as efficiently as a shorter molecule. The 
MPT has been correlated with a series of deleterious effects to the cell, including mitochondrial depolarization, ATP 
depletion and cell death, which is often associated with necrotic cell death [24,40]. In fact, MPT pore induction, 
regardless of the exact mechanism, may well be one of the mechanisms by which some of the triterpenoids here 
described cause mitochondrial dysfunction and cell death. 
5. Conclusion 
From the present study, we can suggest that the new DMAP derivatives compounds are promoting cell death 
through directly targeting mitochondria of breast cancer cells, promoting ROS production, leading to typical 
apoptotic signaling including resulting from MPT induction and from p53 activation to downstream activation of 
caspases. The compounds that were more likely to have these attributes were those with smaller and more complex 
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structure (e.g. four nitrogen atoms coupled to a small side chain). We have also verified that the type of counter ion 
does not seem to influence the higher or lower activity of the compounds. 
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9. Figures Legend 
Fig.1- Chemical structure of the DMAP derivatives used in this study (1 mw 809.986; 2 mw 840.016; 3 mw 
801.084; 4 mw 868.07; 5 mw 868.07; 6 mw 985.02 and 7 mw 985.02 in g/mol), compounds 4, 5 and 6 were 
described in Holy et al [21], while compounds 1, 2, 3 and 7 are new members of that same family. The additional 
groups added to betulinic acid structure are colored (or marked with asterisk in printed version). 
Fig.2 – Effect of DMAP derivatives on tumor and non-tumor cell proliferation. A) normal BJ fibroblast cells, B) 
MCF-12A normal breast cells, C)MDA-MB-231 breast cancer cells, D) MCF-7 breast cancer cells and E) HS578T 
breast cancer cells. 1x104 cells/ml (breast cancer cells) and 2x104 cells/ml (non-tumor cells) were seeded in 48-well 
plates. Cells were grown in glucose medium and incubated during 1, 3 and 5 days with DMAP derivative 
concentrations ranging from 0.125 to 2µg/ml. The compounds tested are shown in Fig.1. Cell proliferation was 
determined by the SRB method and the results are expressed as percentage of control, which represents the density 
of cells without any drug in the respective time point, in order to normalize the growth rate between cell lines. F) the 
recovery of HS578T breast cancer cells after treatment with triterpenoids. HS578T cells were incubated with 
different triterpenoids at concentrations from 0.125 to 2µg/ml for 6 hours, after which the cells were washed and 
fresh medium were added. The graphics represent the moment after washing. All experiments were performed in 
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five independent experiments and are represented as means ± SEM, (*) p<0.05 vs. control using two-way ANOVA 
followed by Bonferroni post-test. 
Fig.3 – DMAP derivatives arrest HS578T cell cycle progression. Compounds (1, 2, 3, 4, 5, 6 and 7) at 0.5 µg/ml 
altered HS578T cell cycle after 24 and 48 hours of treatment. Flow cytometry assays showed that all the compounds 
lead to an increase of cell number in G1/G0 phase, while cells in S-phase decreased. Data are means ± SEM of 5 
separate experiments, (*) p<0.05 vs. control, one-way ANOVA followed by Bonferroni correction for multiple 
comparisons.   
Fig.4 – DMAP derivatives promote caspases-dependent cell death. HS578T breast cells were treated with 
compounds 2, 3, 5 and 7, at 1µg/ml for 24 and 48 hours and A) the Live/Dead Kit was used to measure the number 
of live and dead cells by flow cytometry; B) caspase-like activity assay was used to estimate activation of caspase-9 
and caspase-3 after 24hours of treatment. Cell death-related proteins were measured by western blot, namely Pro-
caspase-9 (C), cleaved caspase-3 (C), p53 (D) and Cyclophylin D (D). Data are means ± SEM of 6 separate 
experiments, (*) p<0.05 vs. control, one-way ANOVA followed by Dunnet multiple-comparisons post-test. 
Fig.5 - Triterpenoids disturb mitochondrial polarization and morphology. Non-tumor BJ fibroblasts, MCF-12A and 
HS578Bst breast cells, and the breast cancer cell line HS578T were treated with vehicle or 0.25µg/ml of compounds 
2, 3, 5 and 7 for 6 hours. A) Cells were labeled with TMRM, which accumulatesin mitochondria due to the negative-
inside ∆Ψ, and were imaged by confocal microscopy in order to observe alterations regarding mitochondrial 
polarization. The images are representative of four independent preparations; scale bar represents 10 µm. B) 
Relative TMRM fluorescence standard deviation was measured in each cell line by using Image Processing and 
Analysis in Java (NIH). Data are means ± SEM of 4 independent measurements, (*) p<0.05 vs. control, one-way 
ANOVA followed by Bonferroni for multiple comparisons post-test. 
Fig.6 - Effects of triterpenoids on breast cancer cells proliferation in glucose-free, galactose/glutamine media. 
Human breast cancer MDA-MB-231 cell line (A), MCF-7 breast cancer cells (B) and HS578T breast cancer cells 
(C) were cultured in galactose/glutamine medium, and incubated with different concentrations of triterpenoids, 
namely compounds 2, 3, 5 and 7 for 1, 3 and 5 days. Differences were found between toxicity in the high-glucose 
and galactose media (see Fig.2). Cell proliferation was accessed by SRB and the results are expressed as a 
percentage of the control. Data are means ± SEM of 5 separate experiments, (*) p<0.05 vs. control, two-way 
ANOVA followed by Bonferroni for multiple comparisons post-test. 
Fig.7 - Effects of compound 2, 3, 5 and 7 on rat liver MPT pore induction. A) Representative recording of 
mitochondrial swelling assays, evaluated by measuring pseudo-absorbance at 540nm, as described in the Materials 
and Methods section. Swelling amplitude was calculated as the difference between the basal absorbance value and 
the absorbance read 600s after calcium addition (40 nmol/mg of protein). Mitochondria were energized with 
succinate in the presence of rotenone. Control (1), compound 5 (2), compound 7 (3), compound 2 (4), compound 3 
(5), cyclosporin A (6; 1µM). The compounds concentration varied from 0.07µg/mg to 1.33 µg/mg of protein, which 
are the same as tested in cell cultures. B) Swelling amplitude data was calculated means ± SEM of 6 different 
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preparations. (*) Significant difference compared to control (p< 0.05), (#) significant difference compared to 
cyclosporin A (p< 0.05), one-way ANOVA and Bonferroni for multiple comparisons post-test.  
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